Molecular biomarkers that can be detected in easily accessible body fluids have been proposed as non-invasive, cost-effective, and useful tools for cancer diagnosis. Recently, extensive research has explored the involvement of the aberrant expression of microRNA-21 (miRNA-21, miR-21) in lung cancer. Inconsistent results, however, have prevented its widespread use in diagnosis. In light of this situation, our meta-analysis aimed to systematically determine whether aberrant miR-21 expression can distinguish patients with lung cancer from cancer-free controls with a high level of diagnostic accuracy. A comprehensive literature search for relevant studies published before December 23, 2013 was conducted in the MEDLINE, EMBASE, the Cochrane Library, and three Chinese databases. The pooled sensitivity, specificity and other parameters were used to assess the overall performance of miR-21-based assays. Statistical analysis was conducted using the STATA 11.0 software. Eleven research articles involving 676 patients with lung cancer and 529 healthy controls were considered eligible for inclusion in the present meta-analysis. The following summary parameters were calculated from all the included studies: sensitivity of 0.66 (95 % confidence interval [CI]: 0.57–0.74), specificity of 0.82 (95 % CI: 0.74–0.88), positive likelihood ratio (PLR) of 3.70 (95 % CI: 2.50–5.60), negative likelihood ratio (NLR) of 0.42 (95 % CI: 0.32–0.54); diagnostic odds ratio (DOR) of 9.00 (95 % CI: 5.00–16.00), and area under the curve (AUC) of 0.81 (95 % CI: 0.77–0.84). In addition, we added two pre-specified covariates (ethnicity and specimen types) to the bivariate model to assess their impact on the diagnostic value of miR-21 for lung cancer. Similar results were also observed in subgroup analyses, indicating a relatively low level of accuracy. The current meta-analysis indicates that a single miR-21 may not be sufficient to identify lung cancer and that more miRNAs should be used to detect lung carcinoma.
MicroRNA-21 Lung cancer Diagnosis Meta-analysis
This is a preview of subscription content, log in to check access.
The science and technology projects from the Science and Technology Committee of Yuzhong District in Chongqing.
O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011;12:795–805. doi:10.1016/S1470-2045(11)70189-9.CrossRefPubMedGoogle Scholar
Zang W, Wang Y, Du Y, Xuan X, Wang T, Li M, et al. Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma. Tumour Biol. 2013. doi:10.1007/s13277-013-1432-5.Google Scholar
Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766–70. doi:10.1038/ng1590.CrossRefPubMedGoogle Scholar
Capodanno A, Boldrini L, Proietti A, Ali G, Pelliccioni S, Niccoli C, et al. Let-7 g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. Int J Oncol. 2013;43:765–74. doi:10.3892/ijo.2013.2003.PubMedGoogle Scholar
Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9.PubMedCentralCrossRefPubMedGoogle Scholar
Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer. 2011;30:407–14.PubMedCentralCrossRefPubMedGoogle Scholar
Huang Y, Hu Q, Deng Z, Hang Y, Wang J, Wang K. MicroRNAs in body fluids as biomarkers for non-small cell lung cancer: a systematic review. Technol Cancer Res Treat. 2013. doi:10.7785/tcrt.2012.500377.Google Scholar